Oncogenic mutations of PIK3CA in human cancers.

[1]  U. Stendahl,et al.  Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. , 2009, International journal of oncology.

[2]  R. Pearson,et al.  Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus , 2006, International journal of cancer.

[3]  A. Hui,et al.  PIK3CA mutations in nasopharyngeal carcinoma , 2006, International journal of cancer.

[4]  A. Marchetti,et al.  PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma , 2006, The Journal of pathology.

[5]  B. Iacopetta,et al.  PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.

[6]  Frank McCormick,et al.  High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. , 2005, Cancer research.

[7]  M. Santoro,et al.  Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.

[8]  G. Reifenberger,et al.  Genetic alteration and expression of the phosphoinositol‐3‐kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas , 2005, Neuropathology and applied neurobiology.

[9]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[10]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[11]  P. Ladenson,et al.  Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[12]  S. Schwartz,et al.  The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.

[13]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[14]  Xin Huang,et al.  Somatic mutation and gain of copy number of PIK3CA in human breast cancer , 2005, Breast Cancer Research.

[15]  D. Louis,et al.  Mutations of the PIK3CA gene are rare in human glioblastoma , 2005, Acta Neuropathologica.

[16]  Christian Hartmann,et al.  PIK3CA mutations in glioblastoma multiforme , 2005, Acta Neuropathologica.

[17]  A. Lash,et al.  Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.

[18]  P. Khavari,et al.  Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.

[19]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[20]  A. Børresen-Dale,et al.  PIK3CA mutations in advanced ovarian carcinomas , 2005, Human mutation.

[21]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[22]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Wei Zhao,et al.  Mutations of PIK3CA in gastric adenocarcinoma. , 2005 .

[24]  P. Massion,et al.  Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. , 2004, American journal of respiratory and critical care medicine.

[25]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[26]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[27]  R. McLendon,et al.  Mutations of PIK3CA in Anaplastic Oligodendrogliomas, High-Grade Astrocytomas, and Medulloblastomas , 2004, Cancer Research.

[28]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[29]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[30]  G. Reifenberger,et al.  Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidyl‐lnositol‐3′‐Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas , 2003, Brain pathology.

[31]  N. Yang,et al.  The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. , 2003, Cancer research.

[32]  G. Parmigiani,et al.  Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers , 2003, Science.

[33]  Kyucheol Cho,et al.  Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma , 2003, International journal of cancer.

[34]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[35]  M. Wolter,et al.  Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components , 2002, Genes, chromosomes & cancer.

[36]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[37]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[38]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[39]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[40]  John F. Timms,et al.  Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .

[41]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[42]  R. Reynolds,et al.  Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. , 2000, International journal of oncology.

[43]  Chen-Yang Shen,et al.  PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.

[44]  P. Guldberg,et al.  Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. , 2000, The Journal of investigative dermatology.

[45]  M. Waterfield,et al.  Signaling by distinct classes of phosphoinositide 3-kinases. , 1999, Experimental cell research.

[46]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[47]  W. Cavenee,et al.  In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[48]  F. Haluska,et al.  Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines , 1998, Oncogene.

[49]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[50]  D. Pinkel,et al.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.

[51]  P. Guldberg,et al.  Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.

[52]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[53]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[54]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[55]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[56]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Trent,et al.  Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. , 1995, Cancer genetics and cytogenetics.

[58]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[59]  K. Kinzler,et al.  Molecular determinants of dysplasia in colorectal lesions. , 1994, Cancer research.

[60]  J. Biegel,et al.  Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma , 1993, Nature Genetics.

[61]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Testa,et al.  A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.

[63]  L. Cantley,et al.  Oncogenes and signal transduction , 1991, Cell.

[64]  S. Staal.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[65]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.